Neurofilament Light Chain (NF-L)

Where the papers sit

20 papers from the last 6 months study Neurofilament Light Chain (NF-L) directly · updated from PubMed 12 Oct 2026

• NfL and GFAP Biomarkers

  Blood and CSF NfL and GFAP are being tested as markers of neuronal and glial injury across diverse neurological presentations. Single Molecule Array measurements recur in hepatic encephalopathy, myasthenia gravis, multiple sclerosis, epilepsy, autoimmune encephalitis, transient ischemic attack, and paediatric psychiatry. The work is moving toward minimally invasive diagnosis and prognosis, but disease specificity remains limited. How these markers should be interpreted across compartments and disorders remains open.

  8 papers · 40%

• NfL in Multiple Sclerosis

  Clinical NfL testing in multiple sclerosis is moving toward standardized, age-aware interpretation rather than a raw concentration alone. Roche, Fujirebio and Siemens assays are being compared, while age- and eGFR-adjusted reference ranges address major sources of variation. Plasma NfL adds prognostic information beyond MRI for disability and radiological progression, with EDSS and biological-age gaps as recurring outcomes. Its role as a surrogate in GM2 gangliosidosis broadens validation, but prospective treatment-response evidence remains limited.

  6 papers · 30%

• Alzheimer Biomarkers in Down Syndrome

  Plasma NfL and Alzheimer biomarkers are being followed longitudinally to connect biological change with cognitive decline in Down syndrome. Proteomic and cognitive trajectories support earlier detection across the Alzheimer spectrum, but the timing and screening value of individual markers remain unsettled. Prion disease cohorts test whether Alzheimer plasma signatures retain specificity outside the target disorder. The field is therefore moving toward multimarker, longitudinal interpretation rather than a single screening analyte.

  3 papers · 15%

• NfL in Neuroaxonal Injury

  Plasma NfL is being positioned as a marker of neuroaxonal injury across treatment-related, metabolic and motor-neuron disease. Longitudinal measurements paired with patient-reported outcomes aim to track vincristine-associated peripheral neuropathy, while diabetes studies relate NfL to neuropathy, age and renal function. In ALS, NfL outperforms inflammatory, metabolic and blood–brain barrier markers for prognosis, supporting its use alongside rather than instead of clinical measures. Whether it can detect early or treatment-responsive peripheral nerve damage remains unresolved.

  3 papers · 15%